+

WO1991001742A1 - Compositions biologiquement actives - Google Patents

Compositions biologiquement actives Download PDF

Info

Publication number
WO1991001742A1
WO1991001742A1 PCT/GB1990/001182 GB9001182W WO9101742A1 WO 1991001742 A1 WO1991001742 A1 WO 1991001742A1 GB 9001182 W GB9001182 W GB 9001182W WO 9101742 A1 WO9101742 A1 WO 9101742A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
officinalis
plant
valeariana
extract
Prior art date
Application number
PCT/GB1990/001182
Other languages
English (en)
Inventor
Christer Stenbacka
Gert Rolad Ohlsson
Sven Thorngvist
Original Assignee
Ruffles, Graham, Keith
Medical Resource (Holdings) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruffles, Graham, Keith, Medical Resource (Holdings) Limited filed Critical Ruffles, Graham, Keith
Publication of WO1991001742A1 publication Critical patent/WO1991001742A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/19—Acanthaceae (Acanthus family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane

Definitions

  • the present invention provides biologically active compositions, notably anti-viral compositions, and in particular compositions effective against HIV.
  • compositions of this invention are based on one or more active ingredients present in the plant Valeariana officinalis and/or Andrographis paniculata, especially active ingredients present in the roots of such plants.
  • compositions of this invention are based on active ingredients present in dry comminuted roots of V ; _ officinalis and/or A. paniculata. If desired, the roots or other part of the plant can be subjected to an ethanol or aqueous extraction in conventional manner.
  • compositions are preferably based on Valeariana officinalis, which ingredient preferably comprises 35 to 60 % of the composition, typically 40 to 50 % of the composition.
  • compositions of this invention are non-toxic, and preferably take the form of compositions for oral administration, such as tablets, though other dosage forms are not precluded.
  • the compositions can contain auxilliary components, such as enzyme precursors, coenzymes, and related bioactive compounds, for example ⁇ hymotripsinogen A, coenzyme Q 1Q , lecithin, alpha-tocopherol, vitamins, nicotini ⁇ acid, and/or pyridoxine hydrochloride.
  • Royal jelly is another useful ingredient. Extracts of other plants may also be incorporated, for instance extracts of Epilobium roseum, Agropyron ⁇ aninum, and/or Salvi officinalis.
  • compositions based on the active ingredients without necessarily obtaining these active ingredients from the plant sources. If the enzyme theory expressed below is substantiated, then the one or more enzymes can be adopted.
  • Retrovirus like HIV can not reproduce without having access to DNA.
  • the HIV-virus has to enter a cell in which it produces a DNA replica of its own RNA moiety.
  • the active signal substance enters the protein shell of the virus infected cell and give orders which make the protein shell decompose. The remainder of the virus-infected cell will then be taken care of by the T-cells.
  • compositions Apart from activity against HIV, the present compositions have a more general anti-viral activity and also have antineoplastic, antibacterial and immunomodulatory activity.
  • the resulting mixture prepared in this manner is identified by us as NR-2, and was submitted for testing.
  • Figure 1 shows the results of toxicity testing of the tablets at the various indicated dilutions.
  • Figure 2 shows the results of related toxicity testing using cells infected with HIV.
  • Figure 3 shows the results on testing at various dilutions on a human tumour cell line.
  • Figure 4 shows the results on testing at various dilutions on a human melanoma cell line.
  • Example 3 0.5g tablets. A normal dose is calculated to be 4 tablets per day.
  • the test diagrams are the same for the tablets as for the powder of Example 1.
  • Effective tablets can also be made by grinding the dried roots.
  • the following ingredients are then particularly suitable:
  • the Valeriana officinalis, o-tocopherol, and vitamins are pre-mixed, dried at 80 * C, ground to a powder, and then mixed with the other ingredients before tabletting in conventional manner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Les compositions présentant une activité antivirale, antinéoplastique, antibactérienne et/ou immunomodulatrice comprennent un ou plusieurs ingrédients obtenus à partir de la plante Valeariana officinalis et/ou Andrographis paniculata.
PCT/GB1990/001182 1989-07-28 1990-07-30 Compositions biologiquement actives WO1991001742A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8917295.1 1989-07-28
GB898917295A GB8917295D0 (en) 1989-07-28 1989-07-28 Anti-viral compositions

Publications (1)

Publication Number Publication Date
WO1991001742A1 true WO1991001742A1 (fr) 1991-02-21

Family

ID=10660788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1990/001182 WO1991001742A1 (fr) 1989-07-28 1990-07-30 Compositions biologiquement actives

Country Status (3)

Country Link
AU (1) AU6272490A (fr)
GB (1) GB8917295D0 (fr)
WO (1) WO1991001742A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017605A1 (fr) * 1994-12-06 1996-06-13 Paracelsian, Inc. Utilisation de composes andrographolide dans le traitement ou l a prevention de la pathogenicite de certaines maladies
WO1999033866A3 (fr) * 1997-12-27 1999-09-10 Gsf Forschungszentrum Umwelt Oligopeptides
WO2001085710A1 (fr) * 2000-05-05 2001-11-15 Dr. Reddy's Research Foundation Composes anticancereux, procede de fabrication, et compositions pharmaceutiques renfermant ces composes
US6410590B1 (en) 2000-02-03 2002-06-25 Dr. Reddy's Research Foundation Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
US6486196B2 (en) 2000-05-05 2002-11-26 Dr. Reddy's Research Foundation Anticancer compounds: process for their preparation and pharmaceutical compositions containing them
US6576662B2 (en) 2000-05-05 2003-06-10 Dr. Reddy's Laboratories Limited Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them
US7135164B2 (en) * 2001-11-09 2006-11-14 Mahidol University Andrographis paniculata gel as an adjunct in the treatment of periodontitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE149731C (fr) * 1902-11-20

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE149731C (fr) * 1902-11-20

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017605A1 (fr) * 1994-12-06 1996-06-13 Paracelsian, Inc. Utilisation de composes andrographolide dans le traitement ou l a prevention de la pathogenicite de certaines maladies
WO1999033866A3 (fr) * 1997-12-27 1999-09-10 Gsf Forschungszentrum Umwelt Oligopeptides
US6410590B1 (en) 2000-02-03 2002-06-25 Dr. Reddy's Research Foundation Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them
WO2001085710A1 (fr) * 2000-05-05 2001-11-15 Dr. Reddy's Research Foundation Composes anticancereux, procede de fabrication, et compositions pharmaceutiques renfermant ces composes
US6486196B2 (en) 2000-05-05 2002-11-26 Dr. Reddy's Research Foundation Anticancer compounds: process for their preparation and pharmaceutical compositions containing them
US6576662B2 (en) 2000-05-05 2003-06-10 Dr. Reddy's Laboratories Limited Compounds having anticancer activity : process for their preparation and pharmaceutical compositions containing them
US7135164B2 (en) * 2001-11-09 2006-11-14 Mahidol University Andrographis paniculata gel as an adjunct in the treatment of periodontitis

Also Published As

Publication number Publication date
AU6272490A (en) 1991-03-11
GB8917295D0 (en) 1989-09-13

Similar Documents

Publication Publication Date Title
AU658614B2 (en) Pharmaceutical compositions for the treatment of skin disorders
WO1991001742A1 (fr) Compositions biologiquement actives
US4466960A (en) Analgesic-diuretic compositions
JP2972807B2 (ja) 老化防止食品及びその製造法
WO2021109511A1 (fr) Composition antifatigue et son procédé de préparation
JPH04243832A (ja) 自己免疫疾患治療剤
RU2000120474A (ru) Фармацевтическая композиция, обладающая противоопухолевой активностью и способ ее получения
CN103566282B (zh) 一种抗肿瘤作用中药组合物及制备方法
CA2248092A1 (fr) Extraits d'harpagophytum procumbens enrichi en harpagoside et leurs procedes de production
US6162438A (en) Herbal compositions and their use as agents for control of hypertension, hypercholesterolemia and hyperlipidemia
CN104127449A (zh) 一种辅助抑制肿瘤的灵芝组合胶囊及其制备方法
JP2002205949A (ja) 代謝異常改善方法およびそのための組成物
JP2525484B2 (ja) 骨粗鬆症治療剤
JPH09208479A (ja) 柳混合物
JPS58172320A (ja) 抗高脂血症剤及びその製造方法
WO1994018994A1 (fr) Composition therapeutique a base d'herbes
JP2905911B2 (ja) Ａｉｄｓにおけるヘルパーｔ細胞数の減少抑制若しくは増加剤
KR100977583B1 (ko) 불미나리에서 간세포 보호 및 간손상 예방 효능을 갖는카페익산을 추출하는 방법 및 이를 포함하는 기능성건강지향식품
RU2274400C1 (ru) Биологически активная добавка для снижения алкогольной зависимости на основе расторопши пятнистой
JP7162357B2 (ja) 桂皮酸誘導体の吸収促進剤
JPH0733675A (ja) 血中脂質改善剤及びこれを含有する組成物
KR20030089253A (ko) 면역활성 및 항암 효과 증진용 조성물
JPS61194031A (ja) 制癌作用増強剤
US7160561B2 (en) Herbal composition and method of treating HIV infection
EP0631785A1 (fr) Solution minérale ionienne, agent contre le virus humain d'immuno-déficience et agent pour le traitement du SIDA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载